BB&T Securities LLC Grows Stake in Becton Dickinson and Co (BDX)

BB&T Securities LLC boosted its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 108,921 shares of the medical instruments supplier’s stock after buying an additional 1,370 shares during the quarter. BB&T Securities LLC’s holdings in Becton Dickinson and were worth $23,315,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Legacy Advisors LLC boosted its stake in Becton Dickinson and by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 490 shares in the last quarter. Amica Retiree Medical Trust boosted its stake in Becton Dickinson and by 325.0% in the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after acquiring an additional 390 shares in the last quarter. Almanack Investment Partners LLC. acquired a new stake in Becton Dickinson and in the fourth quarter valued at approximately $109,000. FTB Advisors Inc. boosted its stake in Becton Dickinson and by 114.2% in the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 290 shares in the last quarter. Finally, Advisors Preferred LLC acquired a new stake in Becton Dickinson and in the fourth quarter valued at approximately $126,000. 83.40% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of Becton Dickinson and stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the transaction, the director now owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP James W. Borzi sold 4,048 shares of Becton Dickinson and stock in a transaction on Monday, February 26th. The shares were sold at an average price of $224.98, for a total transaction of $910,719.04. Following the completion of the transaction, the executive vice president now directly owns 5,334 shares of the company’s stock, valued at approximately $1,200,043.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 281,108 shares of company stock valued at $61,321,396. 1.00% of the stock is currently owned by corporate insiders.

Shares of Becton Dickinson and stock traded down $4.63 during trading on Friday, hitting $215.50. 1,320,570 shares of the company’s stock were exchanged, compared to its average volume of 1,153,007. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93. Becton Dickinson and Co has a 52-week low of $175.66 and a 52-week high of $248.39. The stock has a market cap of $58,607.96, a PE ratio of 22.73, a price-to-earnings-growth ratio of 1.60 and a beta of 1.15.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter last year, the company posted $2.33 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. equities analysts expect that Becton Dickinson and Co will post 10.95 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 30th. Investors of record on Friday, March 9th were issued a dividend of $0.75 per share. The ex-dividend date was Thursday, March 8th. This represents a $3.00 annualized dividend and a dividend yield of 1.39%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 31.65%.

Several equities research analysts have weighed in on the stock. Piper Jaffray restated an “overweight” rating and issued a $260.00 target price (up from $223.00) on shares of Becton Dickinson and in a research note on Tuesday, February 6th. Citigroup upgraded shares of Becton Dickinson and from a “sell” rating to a “neutral” rating in a research note on Friday, January 5th. Zacks Investment Research downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. Finally, BMO Capital Markets started coverage on shares of Becton Dickinson and in a research note on Monday, March 5th. They set a “market perform” rating and a $249.00 price objective for the company. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus price target of $240.53.

TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/bbt-securities-llc-raises-position-in-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply